American Journal of Kidney Diseases
Volume 55, Issue 1 , Pages 100-112 , January 2010

Association of Hemodialysis Treatment Time and Dose With Mortality and the Role of Race and Sex

  • Jessica E. Miller, MPH

      Affiliations

    • Harold Simmons Center for Chronic Disease Research and Epidemiology, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA
    • Department of Epidemiology, UCLA School of Public Health, Los Angeles, CA
    • ,
  • Csaba P. Kovesdy, MD

      Affiliations

    • Salem Veterans Affairs Medical Center, Salem, VA
    • ,
  • Allen R. Nissenson, MD

      Affiliations

    • DaVita Inc, El Segundo, Los Angeles, CA
    • David Geffen School of Medicine at UCLA, Los Angeles, CA
    • ,
  • Rajnish Mehrotra, MD

      Affiliations

    • David Geffen School of Medicine at UCLA, Los Angeles, CA
    • ,
  • Elani Streja, MPH

      Affiliations

    • Harold Simmons Center for Chronic Disease Research and Epidemiology, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA
    • Department of Epidemiology, UCLA School of Public Health, Los Angeles, CA
    • ,
  • David Van Wyck, MD

      Affiliations

    • DaVita Inc, El Segundo, Los Angeles, CA
    • Department of Medicine, Arizona Center on Aging, Arizona Health Sciences Center, Tucson, AZ
    • Department of Surgery, Arizona Center on Aging, Arizona Health Sciences Center, Tucson, AZ
    • ,
  • Sander Greenland, DrPH

      Affiliations

    • Department of Epidemiology, UCLA School of Public Health, Los Angeles, CA
    • Department of Statistics, UCLA College of Letters and Sciences, Los Angeles, CA
    • ,
  • Kamyar Kalantar-Zadeh, MD, MPH, PhD

      Affiliations

    • Harold Simmons Center for Chronic Disease Research and Epidemiology, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA
    • Department of Epidemiology, UCLA School of Public Health, Los Angeles, CA
    • David Geffen School of Medicine at UCLA, Los Angeles, CA
    • Corresponding Author InformationAddress correspondence to Kamyar Kalantar-Zadeh, MD, MPH, PhD, Harold Simmons Center for Chronic Disease Research and Epidemiology, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1124 West Carson St, C1-Annex, Torrance, CA 90509-2910

Received 4 February 2009 ,Accepted 7 August 2009.

References 

  1. US Renal Data System. US Renal Data System 2006 Annual Data Report. Am J Kidney Dis. 2007;49:1–296
  2. Suri RS, Garg AX, Chertow GM, et al. Frequent Hemodialysis Network (FHN) randomized trials: study design. Kidney Int. 2007;71:349–359
  3. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002;347:2010–2019
  4. Gotch FA, Sargent JA. A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int. 1985;28:526–534
  5. Daugirdas JT. The post:pre dialysis plasma urea nitrogen ratio to estimate K.t/V and nPCR: validation. Int J Artif Organs. 1989;12:420–427
  6. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Hemodialysis Adequacy. Am J Kidney Dis. 1998;
  7. National Kidney Foundation. Clinical Practice Guidelines for Hemodialysis Adequacy, update 2006. Am J Kidney Dis. 2006;48(suppl 1):S2–S90
  8. Kurella M, Chertow GM. Dialysis session length (“t”) as a determinant of the adequacy of dialysis. Semin Nephrol. 2005;25:90–95
  9. Basile C, Lomonte C. Dialysis time is the crucial factor in the adequacy of hemodialysis. Kidney Int. 2008;74:965–966
  10. Kalantar-Zadeh K, Lee GH, Miller JE, et al. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis. 2009;53:823–834
  11. Kalantar-Zadeh K, Regidor DL, Kovesdy CP, et al. Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. Circulation. 2009;119:671–679
  12. Regidor DL, Kovesdy CP, Mehrotra R, et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol. 2008;19:2193–2203
  13. Shinaberger CS, Greenland S, Kopple JD, et al. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?. Am J Clin Nutr. 2008;88:1511–1518
  14. Shinaberger CS, Kopple JD, Kovesdy CP, et al. Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2008;3:1769–1776
  15. Streja E, Kovesdy CP, Greenland S, et al. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis. 2008;52:727–736
  16. Kalantar-Zadeh K, Supasyndh O, Lehn RS, McAllister CJ, Kopple JD. Normalized protein nitrogen appearance is correlated with hospitalization and mortality in hemodialysis patients with Kt/V greater than 1.20. J Ren Nutr. 2003;13:15–25
  17. Depner TA. Hemodialysis adequacy: basic essentials and practical points for the nephrologist in training. Hemodial Int. 2005;9:241–254
  18. Shinaberger CS, Kilpatrick RD, Regidor DL, et al. Longitudinal associations between dietary protein intake and survival in hemodialysis patients. Am J Kidney Dis. 2006;48:37–49
  19. Bross R, Zitterkoph J, Pithia J, et al. Association of serum total iron-binding capacity and its changes over time with nutritional and clinical outcomes in hemodialysis patients. Am J Nephrol. 2009;29:571–581
  20. Shantouf R, Kovesdy CP, Kim Y, et al. Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2009;4:1106–1114
  21. Rambod M, Kovesdy CP, Bross R, Kopple JD, Kalantar-Zadeh K. Association of serum prealbumin and its changes over time with clinical outcomes and survival in patients receiving hemodialysis. Am J Clin Nutr. 2008;88:1485–1494
  22. Rambod M, Kovesdy CP, Kalantar-Zadeh K. Malnutrition-inflammation score for risk stratification of patients with CKD: is it the promised gold standard?. Nat Clin Pract Nephrol. 2008;4:354–355
  23. Rambod M, Kovesdy CP, Kalantar-Zadeh K. Combined high serum ferritin and low iron saturation in hemodialysis patients: the role of inflammation. Clin J Am Soc Nephrol. 2008;3:1691–1701
  24. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989;8:551–561
  25. Kalantar-Zadeh K, Kovesdy CP, Derose SF, Horwich TB, Fonarow GC. Racial and survival paradoxes in chronic kidney disease. Nat Clin Pract Nephrol. 2007;3:493–506
  26. Kalantar-Zadeh K, Abbott KC, Kronenberg F, Anker SD, Horwich TB, Fonarow GC. Epidemiology of dialysis patients and heart failure patients. Semin Nephrol. 2006;26:118–133
  27. Kalantar-Zadeh K, Derose SF, Nicholas S, Benner D, Sharma K, Kovesdy CP. Burnt-out diabetes: impact of chronic kidney disease progression on the natural course of diabetes mellitus. J Ren Nutr. 2009;19:33–37
  28. Rambod M, Bross R, Zitterkoph J, et al. Association of malnutrition-inflammation score with quality of life and mortality in hemodialysis patients: a 5-year prospective cohort study. Am J Kidney Dis. 2009;53:298–309
  29. Kovesdy CP, Kalantar-Zadeh K. Why is protein-energy wasting associated with mortality in chronic kidney disease?. Semin Nephrol. 2009;29:3–14
  30. Kalantar-Zadeh K, Kopple JD, Kamranpour N, Fogelman AM, Navab M. HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int. 2007;72:1149–1156
  31. Kalantar-Zadeh K, Duong U, Dukkipati R, Patel T, Dezfuli A, Kovesdy CP. Kidney bone disease and mortality in CKD: the role of vitamin D, alkaline phosphatase and minerals. Kidney Int Suppl. 2010;[in press]
  32. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70:771–780
  33. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006;17:1181–1191
  34. Kalantar-Zadeh K, Aronoff GR. Hemoglobin variability in anemia of chronic kidney disease. J Am Soc Nephrol. 2009;20:479–487
  35. Kalantar-Zadeh K, Streja E, Miller JE, Nissenson AR. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?. Adv Chronic Kidney Dis. 2009;16:143–151
  36. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, et al. Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction. Nephrol Dial Transplant. 2005;20:1880–1888
  37. Combe C, Chauveau P, Laville M, et al. Influence of nutritional factors and hemodialysis adequacy on the survival of 1,610 French patients. Am J Kidney Dis. 2001;37(suppl 1):S81–S88
  38. Shinzato T, Nakai S, Akiba T, et al. Survival in long-term haemodialysis patients: results from the annual survey of the Japanese Society for Dialysis Therapy. Nephrol Dial Transplant. 1997;12:884–888
  39. Wolfe RA, Ashby VB, Daugirdas JT, Agodoa LY, Jones CA, Port FK. Body size, dose of hemodialysis, and mortality. Am J Kidney Dis. 2000;35:80–88
  40. Port FK, Ashby VB, Dhingra RK, Roys EC, Wolfe RA. Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol. 2002;13:1061–1066
  41. Owen WF, Chertow GM, Lazarus JM, Lowrie EG. Dose of hemodialysis and survival: differences by race and sex. JAMA. 1998;280:1764–1768
  42. Lowrie EG, Chertow GM, Lew NL, Lazarus JM, Owen WF. The urea [clearance x dialysis time] product (Kt) as an outcome-based measure of hemodialysis dose. Kidney Int. 1999;56:729–737
  43. Collins AJ, Ma JZ, Umen A, Keshaviah P. Urea index and other predictors of hemodialysis patient survival. Am J Kidney Dis. 1994;23:272–282
  44. Saran R, Bragg-Gresham JL, Levin NW, et al. Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int. 2006;69:1222–1228
  45. Held PJ, Port FK, Wolfe RA, et al. The dose of hemodialysis and patient mortality. Kidney Int. 1996;50:550–556
  46. Greene T, Daugirdas J, Depner T, et al. Association of achieved dialysis dose with mortality in the Hemodialysis Study: an example of “dose-targeting bias.”. J Am Soc Nephrol. 2005;16:3371–3380
  47. Greene T. Randomized and observational studies in nephrology: how strong is the evidence?. Am J Kidney Dis. 2009;53:377–388
  48. Lee CP, Zenios SA, Chertow GM. Cost-effectiveness of frequent in-center hemodialysis. J Am Soc Nephrol. 2008;19:1792–1797
  49. Pierratos A. Does frequent nocturnal hemodialysis result in better outcomes than conventional thrice-weekly hemodialysis?. Nat Clin Pract Nephrol. 2008;4:132–133
  50. Cheung AK, Rocco MV, Yan G, et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO Study. J Am Soc Nephrol. 2006;17:546–555
  51. Lowrie EG, Laird NM, Parker TF, Sargent JA. Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study. N Engl J Med. 1981;305:1176–1181
  52. Kovesdy CP, Regidor DL, Mehrotra R, et al. Serum and dialysate potassium concentrations and survival in hemodialysis patients. Clin J Am Soc Nephrol. 2007;2:999–1007
  53. Kalantar-Zadeh K, Regidor DL, Kovesdy CP, et al. Fluid retention is associated with increased cardiovascular mortality in chronic hemodialysis patients. Circulation. 2009;[e-published January 2009]
  54. Greene T. What did we learn from the HEMO Study? (Implications of secondary analyses). Contrib Nephrol. 2005;149:69–82
  55. Rocco MV, Cheung AK, Greene T, Eknoyan G. The HEMO Study: applicability and generalizability. Nephrol Dial Transplant. 2005;20:278–284

 Originally published online as doi:10.1053/j.ajkd.2009.08.007 on October 23, 2009.

PII: S0272-6386(09)01134-2

doi: 10.1053/j.ajkd.2009.08.007

American Journal of Kidney Diseases
Volume 55, Issue 1 , Pages 100-112 , January 2010

Article Tools

* Image Usage & Resolution